BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34979986)

  • 1. The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer.
    Lee YJ; Kim Y; Choi BB; Kim JR; Ko HM; Suh KH; Lee JS
    BMC Cancer; 2022 Jan; 22(1):12. PubMed ID: 34979986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses.
    Park BJ; Cha MK; Kim IH
    BMC Res Notes; 2014 Jan; 7():7. PubMed ID: 24393391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring serum and immunoglobulin G N-glycome as diagnostic biomarkers for early detection of breast cancer in Ethiopian women.
    Gebrehiwot AG; Melka DS; Kassaye YM; Gemechu T; Lako W; Hinou H; Nishimura SI
    BMC Cancer; 2019 Jun; 19(1):588. PubMed ID: 31208374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thioredoxin 1 as a serum marker for ovarian cancer and its use in combination with CA125 for improving the sensitivity of ovarian cancer diagnoses.
    Park BJ; Cha MK; Kim IH
    Biomarkers; 2014 Nov; 19(7):604-10. PubMed ID: 25174623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the diagnostic value of circulating tumor cells with CytoSorter
    Jin L; Zhao W; Zhang J; Chen W; Xie T; Wang L; Fan W; Xie S; Shen J; Zheng H; Hu W; Wei Q; Dong M; Wang Q; Shen J; Liu Y
    Cancer Med; 2020 Mar; 9(5):1638-1647. PubMed ID: 31908156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 8-Hydroxy-2'-deoxyguanosine as a Discriminatory Biomarker for Early Detection of Breast Cancer.
    Nour Eldin EEM; El-Readi MZ; Nour Eldein MM; Alfalki AA; Althubiti MA; Mohamed Kamel HF; Eid SY; Al-Amodi HS; Mirza AA
    Clin Breast Cancer; 2019 Apr; 19(2):e385-e393. PubMed ID: 30683611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BC-DETECT: combined detection of serum HE4 and TFF3 improves breast cancer diagnostic efficacy.
    Abdelrazek MA; Nageb A; Barakat LA; Abouzid A; Elbaz R
    Breast Cancer; 2022 May; 29(3):507-515. PubMed ID: 34994942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Data Driven for Early Breast Cancer Staging using Integrated Mammography and Biopsy.
    Yampaka T; Noolek D
    Asian Pac J Cancer Prev; 2021 Dec; 22(12):4069-4074. PubMed ID: 34967591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
    Chen C; Chen Q; Dong Y; Liu X
    Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection.
    Fredolini C; Pathak KV; Paris L; Chapple KM; Tsantilas KA; Rosenow M; Tegeler TJ; Garcia-Mansfield K; Tamburro D; Zhou W; Russo P; Massarut S; Facchiano F; Belluco C; De Maria R; Garaci E; Liotta L; Petricoin EF; Pirrotte P
    Breast Cancer Res; 2020 Dec; 22(1):135. PubMed ID: 33267867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated levels of thioredoxin 1 in the lungs and sera of idiopathic pulmonary fibrosis, non-specific interstitial pneumonia and cryptogenic organizing pneumonia.
    Iwata Y; Okamoto M; Hoshino T; Kitasato Y; Sakazaki Y; Tajiri M; Matsunaga K; Azuma K; Kawayama T; Kinoshita T; Imaoka H; Fujimoto K; Kato S; Yano H; Aizawa H
    Intern Med; 2010; 49(22):2393-400. PubMed ID: 21088339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
    Fan J; Yu H; Lv Y; Yin L
    Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-C motif chemokine ligand 5 and C-C chemokine receptor type 5: possible diagnostic application in breast cancer patients.
    Dąbrowska E; Przylipiak A; Zajkowska M; Piskór BM; Borowik-Zaręba A; Ławicki S
    Acta Biochim Pol; 2020 Nov; 67(4):539-449. PubMed ID: 33245226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis.
    Phi XA; Houssami N; Hooning MJ; Riedl CC; Leach MO; Sardanelli F; Warner E; Trop I; Saadatmand S; Tilanus-Linthorst MMA; Helbich TH; van den Heuvel ER; de Koning HJ; Obdeijn IM; de Bock GH
    Eur J Cancer; 2017 Nov; 85():31-38. PubMed ID: 28886475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study.
    Buas MF; Rho JH; Chai X; Zhang Y; Lampe PD; Li CI
    Breast Cancer Res Treat; 2015 Sep; 153(2):445-54. PubMed ID: 26319120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of Salivary Sialic Acid Through Nanotechnology: A Useful Biomarker for the Screening of Breast Cancer.
    Hernández-Arteaga AC; de Jesús Zermeño-Nava J; Martínez-Martínez MU; Hernández-Cedillo A; Ojeda-Galván HJ; José-Yacamán M; Navarro-Contreras HR
    Arch Med Res; 2019 Apr; 50(3):105-110. PubMed ID: 31495386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel panel of blood-based microRNAs capable of discrimination between benign breast disease and breast cancer at early stages.
    Sadeghi H; Kamal A; Ahmadi M; Najafi H; Sharifi Zarchi A; Haddad P; Shayestehpour B; Kamkar L; Salamati M; Geranpayeh L; Lashkari M; Totonchi M
    RNA Biol; 2021 Nov; 18(sup2):747-756. PubMed ID: 34793290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.
    Schummer M; Thorpe J; Giraldez MD; Bergan L; Tewari M; Urban N
    PLoS One; 2015; 10(11):e0142911. PubMed ID: 26565788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a panel of complex autoantigens (LGALS3, PHB2, MUC1, and GK2) in combination with CA15-3 for the diagnosis of early-stage breast cancer.
    Zuo X; Chen L; Liu L; Zhang Z; Zhang X; Yu Q; Feng L; Zhao X; Qin T
    Tumour Biol; 2016 Jan; 37(1):1309-17. PubMed ID: 26289852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer.
    Chung L; Moore K; Phillips L; Boyle FM; Marsh DJ; Baxter RC
    Breast Cancer Res; 2014 Jun; 16(3):R63. PubMed ID: 24935269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.